

Magle Group announces resignation of board members

Magle Chemoswed Holding AB (publ) ("Magle Group" or the "Company") announces today that the board members Martin Lidgard and Claudia Lindwall, at their own request, are leaving the Company's board of directors with immediate effect.

Martin Lidgard, board member, and Claudia Lindwall, board member and staff representative, have informed the board members and the Company that they wish to resign from their positions as board members of Magle Group with immediate effect.

After their resignation, Magle Group's board of directors will consist of five board members elected by the general meeting until Magle Group's annual general meeting 2026.

Contacts Aaron

Aaron Wong, Interim CEO, CFO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglepharmaceut.com and www.maglebiopolymers.com Redeye Nordic Growth AB is the company's Certified Adviser.

Attachments

[Magle Group announces resignation of board members](#)